OCD drug tested as potential relief for long COVID 'Brain Fog'
NCT ID NCT05874037
Summary
This study tested whether fluvoxamine, a drug already approved for obsessive-compulsive disorder, could help ease the symptoms of Long COVID, especially problems with thinking and concentration often called 'brain fog.' It involved 191 adults from Missouri and Illinois who had been suffering from Long COVID symptoms for at least three months. Participants were randomly assigned to receive either the drug or a placebo pill for 16 weeks to see if their symptoms improved.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.